Page 22 - Confidence Interval News Today

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted...

In this population cohort study, patients with gout who used sodium-glucose cotransporter-2 inhibitors (SGLT2is) experienced fewer recurrent flares than those using dipeptidyl peptidase 4 inhibitors (DPP-4is). Those who used SGLT2 inhibitors also presented to the emergency department (ED) less frequently for gout-related visits than those using DPP-4is. Evidence Rating Level: 1 (Excellent) Study Rundown: Gout is a

1. In this randomized controlled trial, zilebesiran resulted in reduced serum angiotensinogen levels and lowered blood pressure among patients with hypertension as compared to a placebo. 2. The effect of zilebesiran on blood pressure was consistent in a subgroup with a high salt diet as well as with co-administration with irbesartan. Evidence Rating Level: 1

1. In this observational study, long-acting antiretroviral therapy (LA-ART) was effective at maintaining virologic suppression in persons living with human immunodeficiency virus (PLWH) with preexisting suppression. 2. Long-acting antiretroviral therapy was also effective at demonstrating virologic suppression in PLWH with viremia. Evidence Rating Level: 1 (Excellent) Study Rundown: Daily oral ART for the treatment of

Approved with EC Authorisation for the Treatment of Patients with Metastatic Castration Resistant Prostate Cancer with BRCA1/2 Mutations Approval for

1. In this population cohort study, patients with gout who used sodium-glucose cotransporter-2 inhibitors (SGLT2is) experienced fewer recurrent flares than those using dipeptidyl peptidase 4 inhibitors (DPP-4is). 2. Those who used SGLT2 inhibitors also presented to the emergency department (ED) less frequently for gout-related visits than those using DPP-4is. Evidence Rating Level: 1 (Excellent) Study

Using NHANES data, along with deidentified data from the Optum database, investigators estimate the prevalence of albuminuria testing among people with hypertension or diabetes as well as how the presence or lack of testing might influence prescription of CKD therapies.

1. In this randomized controlled trial, the E-MOTIVE bundle, consisting of early detection and treatment of postpartum hemorrhage, was associated with a lower risk of complications than usual care. 2. The E-MOTIVE treatment bundle also resulted in higher detection rates of postpartum hemorrhage and treatment adherence compared to usual care. Evidence Rating Level: 1 (Excellent) Study

1. In this randomized controlled trial, for patients in a coma post-cardiac arrest, neurologic outcomes were similar at six months between those receiving targeted mild hypercapnia compared to normocapnia. 2. Mortality rates were also comparable at six months between the mild hypercapnia and normocapnia groups. Evidence Rating Level: 1 (Excellent) Study Rundown: Hypoxic-ischemic encephalopathy results

1. In this prospective cohort study, there was a limited association between acute kidney injury (AKI) and worsening kidney function in patients with chronic kidney disease (CKD). 2. There was no significant decrease in estimated glomerular filtration rate (eGFR) after a mild to moderate AKI in patients with CKD. Evidence Rating Level: 1 (Excellent) Study